It is our great pleasure to welcome you to Vienna, Austria, for the eighth European Breast Cancer Conference (EBCC-8). As part of a biennial series of pioneering meetings, the eighth European Breast Cancer Conference is devoted to presenting, educating on, and debating the most up-to-date developments, topics and ideas within the field of breast cancer.
- To continue advancing the rapid translation of clinical research into practice
- To Encourage the integration and coordinated organisation of treatment modalities, and
- To bring together patient representatives, clinicians, health professionals and scientists to continue working together towards delivering equal access and optimal care for breast cancer patients.
Topical discussions on the biology of metastatic breast cancer will improve our understanding of the process of metastasis and enable progressive disease management; key emphasis is also being placed on areas of considerable concern such as barriers to clinical research and the management of both young and elderly patients. There will also be focussed workshops on radiotherapy, surgery, screening and consensus guidelines from our partner societies. The tradition of high quality Oxford-style debates on important controversies is being continued, and the EUROPA DONNA sessions will help to put all the new data into perspective – i.e. what it means for the patient.
The exceptional standards of the keynote symposia, teaching lectures, clinical symposia, debate sessions and outstanding speakers are now being enhanced by a new feature: ‘Patient Day’ which will enable the lay public to talk to experts at local and international level about breast cancer concerns. This encompassing approach will enable EBCC-8 participants to truly focus on the holistic picture of breast cancer, including research, prevention, treatment, advocacy and care.
Late Breaking Abstracts
The 8th European Breast Cancer Committee strongly encourages the submission of Late Breaking Abstracts relating to important data that were not fully available by the general abstract submission deadline. Late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications.
Please select only one topic that refers to the main subject of the abstract. The Scientific Committee has the authority to re-categorise the abstract.
- Adjuvant and Neo-Adjuvant Therapy
- Advocacy and Education
- Detection, Diagnosis and Imaging
- Ductal and Lobular Carcinoma in Situ
- Epidemiology, Prevention, Screening
- Locally Advanced and Metastatic Disease
- Pharmacology, New Drug Development
- Predictive and Prognostic Factors
- Side Effects of Treatment, Follow-up, Management and Care, Psychosocial Aspects
- Surgical Management (Including Reconstructive Surgery and Sentinel Node)
- Targeted Treatment
- Molecular Biology, Tumour Biology and Immunology
- Breast Cancer in Young and Elderly
- Miscellaneous (only if none of the above topics apply to the abstract subject)